14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Jun 09, 2023 $31.10 $31.36 $30.50 $30.52 417 783
Jun 08, 2023 $30.64 $31.10 $29.87 $31.07 552 086
Jun 07, 2023 $30.61 $31.35 $30.02 $30.78 619 837
Jun 06, 2023 $30.51 $30.96 $30.11 $30.58 950 673
Jun 05, 2023 $30.87 $31.58 $30.33 $30.46 630 360
Jun 02, 2023 $31.22 $31.64 $30.72 $31.52 510 352
Jun 01, 2023 $30.22 $31.20 $29.95 $30.92 607 179
May 31, 2023 $29.55 $30.84 $29.35 $30.22 1 364 662
May 30, 2023 $30.09 $30.49 $28.91 $29.27 726 057
May 26, 2023 $29.96 $30.30 $29.52 $29.96 678 806
May 25, 2023 $31.39 $31.34 $29.54 $29.81 757 545
May 24, 2023 $31.64 $31.75 $30.95 $31.40 447 387
May 23, 2023 $31.50 $32.36 $31.33 $31.96 606 741
May 22, 2023 $31.95 $32.76 $31.20 $31.51 730 586
May 19, 2023 $30.81 $31.83 $30.74 $31.58 608 563
May 18, 2023 $29.65 $30.42 $29.16 $30.35 777 579
May 17, 2023 $29.42 $29.86 $28.80 $29.74 503 312
May 16, 2023 $31.38 $31.38 $29.15 $29.30 1 074 268
May 15, 2023 $28.07 $32.61 $28.07 $32.02 1 608 788
May 12, 2023 $27.77 $27.97 $27.35 $27.96 490 399
May 11, 2023 $28.37 $28.56 $27.52 $27.69 676 304
May 10, 2023 $27.61 $28.72 $27.16 $28.37 893 737
May 09, 2023 $26.60 $27.62 $26.14 $27.32 692 194
May 08, 2023 $26.46 $26.66 $26.05 $26.56 394 705
May 05, 2023 $27.00 $27.06 $25.91 $26.52 536 624
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT